论文部分内容阅读
近年来,对急性失代偿心力衰竭的治疗已经从单独地改善血流动力学进展到对神经内分泌的调节,内皮素(ET)是心力衰竭发生机制中重要介质,本文就内皮素受体拮抗剂Tezosentan治疗急性失代偿心力衰竭的药理学以及副作用及安全性的临床研究作一综述,结果发现Tezosentan治疗急性失代偿心力衰竭的研究结果差异很大。因此临床医师在使用此药时应严格掌握临床适应证和禁忌症,同时需要进一步的深入研究明确Tezosentan在急性失代偿心力衰竭中的治疗地位。
In recent years, the treatment of acute decompensated heart failure has been independently improved hemodynamic progress to the regulation of neuroendocrine, endothelin (ET) is an important medium in the pathogenesis of heart failure, endothelin receptor antagonist A review of the pharmacology, side effects and safety of Tezosentan in the treatment of acute decompensated heart failure has led to a very different finding of Tezosentan in the treatment of acute decompensated heart failure. Therefore, clinicians should strictly observe the clinical indications and contraindications when using this drug. At the same time, further research is needed to determine the treatment status of Tezosentan in acute decompensated heart failure.